View More Recent Stories

Aug 4, 2022 08:30AM SAB Biotherapeutics to Host Virtual 2022 Annual R&D Portfolio Update
Jul 11, 2022 08:04AM SAB Biotherapeutics (SABS) Appoints Scott Giberson to its Board
Jul 11, 2022 08:00AM SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors
Jul 5, 2022 08:00AM SAB Biotherapeutics Hosts U.S. Representatives Dusty Johnson and Dean Phillips for South Dakota Facility Tour
Jun 6, 2022 08:31AM SAB Biotherapeutics (SABS) Appoints Alexandra Kropotova as Chief Medical Officer
Jun 6, 2022 08:30AM SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer
May 31, 2022 08:30AM SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit
May 12, 2022 04:15PM SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results
May 12, 2022 09:42AM SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference
May 12, 2022 09:42AM SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference
Apr 5, 2022 06:00AM SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors
Mar 29, 2022 04:30PM SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results
Mar 2, 2022 06:00AM SAB Biotherapeutics (SABS) Announces NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations
Mar 2, 2022 06:00AM SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations
Mar 2, 2022 06:00AM SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations
Mar 2, 2022 05:53AM SAB Biotherapeutics (SABS) Reports Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants
Mar 1, 2022 07:30PM SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants
Feb 25, 2022 06:19AM SAB Biotherapeutics (SABS) Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
Feb 25, 2022 06:00AM SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
Feb 25, 2022 06:00AM SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
Jan 24, 2022 06:00AM SAB Biotherapeutics (SABS) Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3
Jan 24, 2022 06:00AM SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
Jan 24, 2022 06:00AM SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
Jan 5, 2022 07:00AM SAB Biotherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
Jan 5, 2022 07:00AM SAB Biotherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
Dec 20, 2021 06:03AM SAB Biotherapeutics (SABS) Added to NASDAQ Biotechnology Index
Dec 20, 2021 06:00AM SAB Biotherapeutics Added to NASDAQ Biotechnology Index
Dec 20, 2021 06:00AM SAB Biotherapeutics Added to NASDAQ Biotechnology Index
Dec 16, 2021 06:01AM SAB Biotherapeutics (SABS) Reports SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
Dec 16, 2021 06:00AM SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
Dec 16, 2021 06:00AM SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
Dec 1, 2021 07:01AM SAB Biotherapeutics (SABS) Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
Dec 1, 2021 07:00AM SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
Dec 1, 2021 07:00AM SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
Nov 22, 2021 07:00AM SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update
Nov 22, 2021 07:00AM SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update
Oct 25, 2021 07:39AM SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
Oct 25, 2021 07:39AM SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
View More Recent Stories